|
Index of reports
> Serious Reactions (1036)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine serious reactions. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of 1036 Next >>
Possible Vincristine side effects in male
Reported by a health professional (non-physician/pharmacist) from Canada on 2012-08-27
Patient: male
Reactions: Dystonia, Encephalopathy, Parkinsonism
Drug(s) suspected as cause:
Cisplatin
Cyclophosphamide
Etoposide
Ifosfamide
Vincristine
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-08-27
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: 10000 iu, day 8 (2 escalated cycles)
Indication: Hodgkin's Disease
Bleomycin Sulfate
Dosage: 10000 iu, day 8 (4 standard cycles)
Cyclophosphamide
Dosage: 650 mg/m2, day 1 (4 standard cycles)
Cyclophosphamide
Dosage: 1250 mg/m2, day 1 (2 escalated cycles)
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2, day 1 (4 standard cycles)
Doxorubicin HCL
Dosage: 35 mg/m2, day 1 (2 escalated cycles)
Indication: Hodgkin's Disease
Etoposide
Dosage: 100 mg/m2, day 1-3 (4 standard cycles)
Etoposide
Dosage: 200 mg/m2, day 1-3 (2 escalated cycles)
Indication: Hodgkin's Disease
Prednisolone
Dosage: 40 mg/m2, day 1-14 (4 standard cycles)
Administration route: Oral
Prednisolone
Dosage: 40 mg/m2, day 1-14 (2 escalated cycles)
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 100 mg/m2, day 1-7 (2 escalated cycles)
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 100 mg/m2, day 1-7 (4 standard cycles)
Administration route: Oral
Vincristine
Dosage: 1.4 mg/m2, day 8 (2 escalated cycles)
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2, day 8 (4 standard cycles)
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27
Patient:
Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection
Drug(s) suspected as cause:
Carboplatin
Dosage: 6 courses in high risk
Indication: Retinoblastoma
Cyclophosphamide
Indication: Retinoblastoma
Doxorubicin Hydrochloride
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Etoposide
Indication: Retinoblastoma
Vincristine
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-08-27
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: on day 8
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for standard cycles on day 1
Doxorubicin Hydrochloride
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Doxorubicin Hydrochloride
Dosage: on day 1,for standard cycles
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the standard cycles, day 1 to 3
Indication: Hodgkin's Disease
Prednisolone
Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: day 1 to 7
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: on day 8
Indication: Hodgkin's Disease
Possible Vincristine side effects in 47 year old male
Reported by a physician from France on 2012-08-27
Patient: 47 year old male
Reactions: Respiratory Tract Infection Bacterial, Epstein-Barr Virus Associated Lymphoma, Congestive Cardiomyopathy, Systolic Dysfunction
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Start date: 2012-06-08
Doxorubicin HCL
Start date: 2012-06-11
End date: 2012-07-10
Mabthera
Start date: 2012-06-11
Nexium
Administration route: Oral
Prednisolone
Administration route: Oral
Start date: 2012-06-08
Vincristine
Start date: 2012-06-08
Other drugs received by patient: Previscan; Methotrexate Sodium; Potassium Chloride; Kineret; Kineret; Kineret; Cacit D3; Aspirin; Prednisone TAB; Acetaminophen; Acetaminophen W / Codeine; Alendronate Sodium / Cholecalciferol
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-08-24
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: on day 8
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for standard cycles on day 1
Doxorubicin Hydrochloride
Dosage: on day 1,for standard cycles
Doxorubicin Hydrochloride
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the standard cycles, day 1 to 3
Indication: Hodgkin's Disease
Prednisolone
Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: day 1 to 7
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: on day 8
Indication: Hodgkin's Disease
Possible Vincristine side effects in female
Reported by a physician from Bulgaria on 2012-08-24
Patient: female, weighing 63.0 kg (138.6 pounds)
Reactions: Circulatory Collapse, Bone Marrow Failure
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1000 milligram
Indication: Multiple Myeloma
Start date: 2012-05-23
End date: 2012-05-25
Dexamethasone
Dosage: 40 milligram
Start date: 2012-06-02
End date: 2012-06-05
Dexamethasone
Dosage: 40 milligram
Indication: Multiple Myeloma
Start date: 2012-05-23
End date: 2012-05-26
Dexamethasone
Dosage: 20 milligram
Start date: 2012-05-16
End date: 2012-05-19
Doxorubicin Hydrochloride
Dosage: 80 milligram
Indication: Multiple Myeloma
Start date: 2012-05-26
End date: 2012-05-26
Revlimid
Dosage: 25 milligram
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2012-05-30
End date: 2012-06-07
Vincristine
Dosage: 2 milligram
Indication: Multiple Myeloma
Start date: 2012-05-26
End date: 2012-06-02
Other drugs received by patient: Milgamma; Dopamine HCL; Nexium; Atropine; Sodium Carbonate; Lyrica; Uromithexane; Electrolyte Infusions; Sodium Bicarbonate; Probitor; Tevagrastim
Possible Vincristine side effects in 51 year old male
Reported by a physician from Germany on 2012-08-24
Patient: 51 year old male
Reactions: Progressive Multifocal Leukoencephalopathy
Drug(s) suspected as cause:
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Cyclophosphamide
Indication: HIV Infection
Doxorubicin HCL
Indication: HIV Infection
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Mabthera
Indication: non-Hodgkin's Lymphoma
Mabthera
Indication: HIV Infection
Prednisone
Indication: HIV Infection
Prednisone TAB
Indication: non-Hodgkin's Lymphoma
Vincristine
Indication: HIV Infection
Vincristine
Indication: non-Hodgkin's Lymphoma
Possible Vincristine side effects in 52 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-24
Patient: 52 year old female
Reactions: Tumour Lysis Syndrome, Posterior Reversible Encephalopathy Syndrome, Insomnia, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: according to larson regimen
Indication: B Precursor Type Acute Leukaemia
Daunorubicin HCL
Dosage: according to larson regimen
Indication: B Precursor Type Acute Leukaemia
Daunorubicin HCL
Dosage: at 50% dosage
Dexamethasone
Indication: Premedication
Methylprednisolone Sodium Succinate
Indication: B Precursor Type Acute Leukaemia
Prednisone TAB
Dosage: according to larson regimen
Indication: B Precursor Type Acute Leukaemia
Vincristine
Dosage: according to larson regimen
Indication: B Precursor Type Acute Leukaemia
Other drugs received by patient: Ondansetron; Voriconazole; Morphine Sulfate; Morphine
Possible Vincristine side effects in 18 year old female
Reported by a physician from Slovenia on 2012-08-23
Patient: 18 year old female
Reactions: Pulmonary Haemorrhage, Gastrointestinal Haemorrhage, Injection Site Haemorrhage, Sepsis, Shock Haemorrhagic, Acute Respiratory Distress Syndrome, Bone Marrow Failure, Staphylococcal Bacteraemia, Septic Shock
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Heparin
Vincristine
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-08-23
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Septic Shock, Lung Infiltration
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Baxter 15 000 IE Lyofilisat TIL Injeksjonsv?ske / Infusjonsv?s
Cyclophosphamide
Cyclophosphamide
Doxorubicin Hydrochloride
Doxorubicin Hydrochloride
Etoposide
Etoposide
Prednisolone
Administration route: Oral
Procarbazine Hydrochloride
Administration route: Oral
Vincristine
Possible Vincristine side effects in male
Reported by a health professional (non-physician/pharmacist) from Canada on 2012-08-23
Patient: male
Reactions: Dystonia, Encephalopathy, Parkinsonism
Drug(s) suspected as cause:
Cisplatin
Cyclophosphamide
Etoposide
Ifosfamide
Vincristine
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-22
Patient:
Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Coagulopathy, Hypoglycaemia, Hypocalcaemia, Hypoxia, Hiccups, Alanine Aminotransferase Abnormal, Pneumonitis, Cough, Pain in Extremity, Hypotension, Hyperglycaemia, External Ear Pain, Haematotoxicity, Dehydration, Lower Gastrointestinal Haemorrhage, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Hypokalaemia, Blood Bilirubin Abnormal, Pleural Effusion, Decreased Appetite, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, Hypercalcaemia, Hypophosphataemia, Diarrhoea, Hypoalbuminaemia, Hypertension, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin HCL
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate Sodium
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Vancomycin; Posaconazole; Voriconazole; Levofloxacin
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-08-22
Patient: male
Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: on day 1
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Mantle Cell Lymphoma
Leukine
Dosage: on day 9-15; 250 mcg/m2/day
Indication: Diffuse Large B-Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Mantle Cell Lymphoma
Prednisone TAB
Dosage: on days 1-5
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: on day 15; as infusion
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1 (maximum dose: 2mg)
Indication: Mantle Cell Lymphoma
Possible Vincristine side effects in 51 year old male
Reported by a physician from Japan on 2012-08-22
Patient: 51 year old male, weighing 57.7 kg (126.9 pounds)
Reactions: Hypophosphataemia, Tumour Lysis Syndrome, Gastrointestinal Haemorrhage, Metabolic Acidosis, Hyperphosphataemia, Disseminated Intravascular Coagulation
Adverse event resulted in: death
Drug(s) suspected as cause:
Allopurinol
Dosage: 300 mg, unk
Allopurinol
Dosage: 200 mg, unk
Indication: Tumour Lysis Syndrome
Cyclophosphamide
Dosage: 1200 mg, unk
Indication: Lymphoma
Doxorubicin HCL
Dosage: 80 mg, unk
Indication: Lymphoma
Methylprednisolone
Dosage: 250 mg/day
Indication: Lymphoma
Methylprednisolone
Dosage: 60 mg/day
Sodium Bicarbonate
Indication: Metabolic Acidosis
Vincristine
Dosage: 2 mg, unk
Indication: Lymphoma
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-22
Patient:
Reactions: Off Label Use, Gastrointestinal Toxicity
Drug(s) suspected as cause:
Carboplatin
Dosage: 6 courses in high risk
Indication: Retinoblastoma
Cyclophosphamide
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Doxorubicin HCL
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Etoposide
Dosage: 6 courses in high risk
Indication: Retinoblastoma
Vincristine
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in male
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-22
Patient: male
Reactions: Pneumonia Bacterial, Febrile Neutropenia
Drug(s) suspected as cause:
Cisplatin
Dosage: unk
Indication: Thymoma Malignant
Start date: 2011-08-01
Cyclophosphamide
Dosage: unk
Indication: Thymoma Malignant
Start date: 2011-08-01
Doxorubicin HCL
Dosage: unk
Indication: Thymoma Malignant
Start date: 2011-08-01
Vincristine
Dosage: unk
Indication: Thymoma Malignant
Start date: 2011-08-01
Possible Vincristine side effects in male
Reported by a consumer/non-health professional from Germany on 2012-08-21
Patient: male, weighing 86.0 kg (189.2 pounds)
Reactions: Pneumonia, Pulmonary Embolism, Cytomegalovirus Infection, Pulmonary Infarction, Lymphoma, Staphylococcal Sepsis
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 1500 mg, qd (day 1)
Indication: T-Cell Lymphoma
Start date: 2009-12-07
End date: 2010-01-11
Doxorubicin HCL
Dosage: 100 mg, qd (day 1)
Indication: T-Cell Lymphoma
Start date: 2009-12-07
End date: 2010-01-11
Filgrastim
Dosage: 48 unk, qd (day 1)
Indication: T-Cell Lymphoma
Start date: 2009-12-25
End date: 2010-01-15
Mabcampath
Dosage: 30 mg, day 4 and 5 of each cycle 1-3
Indication: T-Cell Lymphoma
Start date: 2009-12-10
End date: 2010-01-15
Prednisone
Dosage: 10 mg, qd (day 1-5)
Administration route: Oral
Indication: T-Cell Lymphoma
Start date: 2009-11-27
End date: 2010-01-10
Vincristine
Dosage: 1 mg, qd (day 1)
Indication: T-Cell Lymphoma
Start date: 2009-11-26
End date: 2010-01-11
Other drugs received by patient: Torsemide; Metoprolol Succinate; Heparin; Marcumar; Pantoprazole; Sulfamethoprim
Possible Vincristine side effects in 77 year old male
Reported by a health professional (non-physician/pharmacist) from China on 2012-08-21
Patient: 77 year old male
Reactions: Adverse Drug Reaction, Diffuse Large B-Cell Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Dexamethasone
Dosage: in cycle 1
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin Hydrochloride
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Methotrexate
Dosage: in cycle 1
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: on days 1 to 5
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: on day 1
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-08-21
Patient: male, weighing 115.7 kg (254.5 pounds)
Reactions: Gastrointestinal Haemorrhage, Cholecystitis Acute, T-Cell Lymphoma, Disseminated Intravascular Coagulation, Pancytopenia, Atrial Fibrillation, Multi-Organ Failure, Sepsis, Acute Respiratory Distress Syndrome
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Adriamycin PFS
Indication: T-Cell Lymphoma
Start date: 2006-09-10
Cyclophosphamide
Indication: T-Cell Lymphoma
Start date: 2006-01-01
Prednisone TAB
Indication: T-Cell Lymphoma
Start date: 2006-01-01
Remicade
Dosage: 3 dose induction followed by maint. q 8 weeks, 300 mg on 29-jun-2006, total 27 infusions
Indication: Rheumatoid Arthritis
Start date: 2001-10-01
End date: 2006-06-29
Vincristine
Indication: T-Cell Lymphoma
Start date: 2006-09-10
Other drugs received by patient: Azulfadine; Lisinopril
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-21
Patient:
Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection
Drug(s) suspected as cause:
Carboplatin
Dosage: 6 courses in high risk
Indication: Retinoblastoma
Cyclophosphamide
Indication: Retinoblastoma
Doxorubicin HCL
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Etoposide
Indication: Retinoblastoma
Vincristine
Dosage: 4 courses in intermediate risk and 6 courses in high risk
Indication: Retinoblastoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in 45 year old female
Reported by a physician from United States on 2012-08-21
Patient: 45 year old female
Reactions: Epstein-Barr Virus Infection, Splenic Infection Fungal, Mycosis Fungoides Refractory, Granuloma, Pneumonia Cytomegaloviral
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Campath
Dosage: unk
Indication: Mycosis Fungoides
Start date: 2006-06-01
Cisplatin
Dosage: unk
Indication: Mycosis Fungoides
Cyclophosphamide
Dosage: unk
Indication: Mycosis Fungoides
Start date: 2006-01-01
Daunorubicin HCL
Dosage: unk
Indication: Mycosis Fungoides
Start date: 2006-01-01
Dexamethasone
Dosage: unk
Indication: Mycosis Fungoides
Etoposide
Dosage: unk
Indication: Mycosis Fungoides
Fludara
Dosage: 2 cycles
Indication: Mycosis Fungoides
Ifosfamide
Dosage: unk
Indication: Mycosis Fungoides
Prednisone
Dosage: unk
Indication: Mycosis Fungoides
Start date: 2006-01-01
Vincristine
Dosage: unk
Indication: Mycosis Fungoides
Start date: 2006-01-01
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Abdominal Pain, Thrombosis, Hyperkalaemia, Hypoglycaemia, Coagulopathy, Hypokalaemia, Blood Bilirubin Abnormal, Hiccups, Pleural Effusion, Hypoxia, Hypocalcaemia, Alanine Aminotransferase Abnormal, Cough, Pneumonitis, Decreased Appetite, Pain in Extremity, Hypotension, Hyperglycaemia, Gamma-Glutamyltransferase Abnormal, Hyponatraemia, External Ear Pain, Hypercalcaemia, Haematotoxicity, Hypophosphataemia, Diarrhoea, Dehydration, Hypoalbuminaemia, Lower Gastrointestinal Haemorrhage, Hypertension, Hypofibrinogenaemia, Aspartate Aminotransferase Abnormal, Infection
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15, 22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 14 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns involvement and on days 8, 15, 22 for cns involvement
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Levofloxacin; Voriconazole; Posaconazole; Vancomycin
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Multi-Organ Failure, Sepsis, Hypoxia
Adverse event resulted in: death, life threatening event
Drug(s) suspected as cause:
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Indication: Acute Lymphocytic Leukaemia
PEG-Asparaginase
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Off Label Use, Zygomycosis
Drug(s) suspected as cause:
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Indication: Acute Lymphocytic Leukaemia
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Asparaginase
Dosage: 2500 units/m2/dose as 4 weekly doses
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Indication: Acute Lymphocytic Leukaemia
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Bortezomib
Dosage: 1.3 mg/sq.m/dose on days 1, 4, 8 and 11 combined with vxld
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15,22 for cns invlovment
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15,22 for cns invlovment
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15,22 for cns invlovment
Cytarabine
Dosage: on day 1 for all patients and on days 8, 15,22 for cns invlovment
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 24 consecutive days
Administration route: Oral
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 24 consecutive days
Administration route: Oral
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 24 consecutive days
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2/day divided in to 2 doses for 24 consecutive days
Administration route: Oral
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Doxorubicin Hydrochloride
Dosage: given over 15-30 minutes on day 1
Hydrocortisone
Dosage: on days 8, 15 and 22
Hydrocortisone
Dosage: on days 8, 15 and 22
Hydrocortisone
Dosage: on days 8, 15 and 22
Hydrocortisone
Dosage: on days 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns invlovement and on days 8, 15, 22 for cns invlovement
Methotrexate
Dosage: 1 dose on day 15 for no cns invlovement and on days 8, 15, 22 for cns invlovement
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: 1 dose on day 15 for no cns invlovement and on days 8, 15, 22 for cns invlovement
Methotrexate
Dosage: 1 dose on day 15 for no cns invlovement and on days 8, 15, 22 for cns invlovement
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Vincristine
Dosage: 1.5 mg/m2/dose, max. 2 mg, by push on days 1, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Multi-Organ Failure, Sepsis, Cerebral Ischaemia
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Indication: Acute Lymphocytic Leukaemia
PEG-Asparaginase
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in 51 year old male
Reported by a physician from Japan on 2012-08-20
Patient: 51 year old male
Reactions: Hypophosphataemia, Metabolic Acidosis, Tumour Lysis Syndrome, Gastrointestinal Haemorrhage, Hyperphosphataemia, Disseminated Intravascular Coagulation
Adverse event resulted in: death
Drug(s) suspected as cause:
Allopurinol
Dosage: unk
Cyclophosphamide
Dosage: 1200 mg, unk
Indication: Lymphoma
Doxorubicin
Dosage: 80 mg, unk
Indication: Lymphoma
Methylprednisolone
Dosage: 60 mg/day
Methylprednisolone
Dosage: 250 mg/day
Indication: Lymphoma
Sodium Bicarbonate
Indication: Metabolic Acidosis
Vincristine
Dosage: 2 mg, unk
Indication: Lymphoma
Possible Vincristine side effects in female
Reported by a physician from United States on 2012-08-20
Patient: female, weighing 70.8 kg (155.8 pounds)
Reactions: Abdominal Pain, Hyperpyrexia, Anaphylactic Reaction, Chills, Pain, Hepatic Failure, Transaminases Increased, Splenic Infarction, Loss of Consciousness, Aortic Thrombosis, Off Label Use, Malaise, C-Reactive Protein Increased, Myositis, Dyspnoea, Hypotension, Arrhythmia, Lung Consolidation, Hypophosphataemia, Zygomycosis, Bacteraemia, Ventricular Tachycardia, Hyperammonaemia, Neutropenia, Hepatic Infarction, Shock, Infusion Related Reaction
Adverse event resulted in: death, life threatening event
Drug(s) suspected as cause:
Cytarabine
Dosage: day 1,8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
Decadron Phosphate
Dosage: day 1
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
Doxil
Dosage: day 1
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Methotrexate
Dosage: day 1
Indication: Acute Lymphocytic Leukaemia
Start date: 2005-01-01
End date: 2007-01-01
PEG-Asparaginase
Dosage: day 2, 8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-25
End date: 2007-10-25
Velcade
Dosage: day 1, 4, 8 and 11
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Vincristine
Dosage: day 1,8, 15 and 22
Indication: Acute Lymphocytic Leukaemia
Start date: 2007-10-23
End date: 2007-10-23
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Gastrointestinal Haemorrhage, Coagulopathy, Escherichia Sepsis
Drug(s) suspected as cause:
Cytarabine
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2, cyclic
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: 60 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: Acute Lymphocytic Leukaemia
PEG-Asparaginase
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in
Reported by a physician from United States on 2012-08-20
Patient:
Reactions: Adrenal Insufficiency, Encephalopathy
Drug(s) suspected as cause:
Cytarabine
Dosage: unk unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Dosage: 10 mg/m2, cyclic
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Doxorubicin Hydrochloride
Dosage: 60 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Hydrocortisone
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
PEG-Asparaginase
Dosage: unk, cyclic
Indication: Acute Lymphocytic Leukaemia
Velcade
Dosage: 1.3 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 1.5 mg/m2, cyclic
Indication: Acute Lymphocytic Leukaemia
Page 1 Next >>
|
